Stock Analysis

Embla Medical hf Third Quarter 2024 Earnings: EPS: US$0.051 (vs US$0.033 in 3Q 2023)

CPSE:EMBLA
Source: Shutterstock

Embla Medical hf (CPH:EMBLA) Third Quarter 2024 Results

Key Financial Results

  • Revenue: US$213.5m (up 11% from 3Q 2023).
  • Net income: US$21.9m (up 57% from 3Q 2023).
  • Profit margin: 10% (up from 7.2% in 3Q 2023). The increase in margin was driven by higher revenue.
  • EPS: US$0.051 (up from US$0.033 in 3Q 2023).
earnings-and-revenue-growth
CPSE:EMBLA Earnings and Revenue Growth October 23rd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Embla Medical hf Earnings Insights

Looking ahead, revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Medical Equipment industry in Europe.

Performance of the market in Denmark.

The company's shares are up 5.8% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Embla Medical hf has 1 warning sign we think you should be aware of.

Valuation is complex, but we're here to simplify it.

Discover if Embla Medical hf might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.